Allergen immunotherapy

Matthew A Rank, James T C Li

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Allergen immunotherapy involves exposing a patient to a gradually escalating dose of a specific allergen with the intention of decreasing allergic and inflammatory responses, ultimately leading to a sustained decrease in allergic symptoms. A build-up phase (once weekly injections) is followed by a maintenance phase (once monthly injections) that generally continues for 3 to 5 years. Allergen immunotherapy is indicated for select patients with allergic rhinoconjunctivitis, allergic asthma, and stinging insect hypersensitivity. The safety and efficacy of allergen immunotherapy have been confirmed by numerous well-designed studies. Recent research has helped uncover the mechanisms by which allergen immunotherapy exerts its therapeutic effect, paving the way for the development of safer, more effective therapy for a wider range of allergic diseases.

Original languageEnglish (US)
Pages (from-to)1119-1123
Number of pages5
JournalMayo Clinic Proceedings
Volume82
Issue number9
DOIs
StatePublished - 2007

Fingerprint

Immunologic Desensitization
Injections
Therapeutic Uses
Allergens
Insects
Hypersensitivity
Asthma
Maintenance
Safety
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Allergen immunotherapy. / Rank, Matthew A; Li, James T C.

In: Mayo Clinic Proceedings, Vol. 82, No. 9, 2007, p. 1119-1123.

Research output: Contribution to journalArticle

Rank, Matthew A ; Li, James T C. / Allergen immunotherapy. In: Mayo Clinic Proceedings. 2007 ; Vol. 82, No. 9. pp. 1119-1123.
@article{505c3c8815654ef99dc77a69ee611bfb,
title = "Allergen immunotherapy",
abstract = "Allergen immunotherapy involves exposing a patient to a gradually escalating dose of a specific allergen with the intention of decreasing allergic and inflammatory responses, ultimately leading to a sustained decrease in allergic symptoms. A build-up phase (once weekly injections) is followed by a maintenance phase (once monthly injections) that generally continues for 3 to 5 years. Allergen immunotherapy is indicated for select patients with allergic rhinoconjunctivitis, allergic asthma, and stinging insect hypersensitivity. The safety and efficacy of allergen immunotherapy have been confirmed by numerous well-designed studies. Recent research has helped uncover the mechanisms by which allergen immunotherapy exerts its therapeutic effect, paving the way for the development of safer, more effective therapy for a wider range of allergic diseases.",
author = "Rank, {Matthew A} and Li, {James T C}",
year = "2007",
doi = "10.4065/82.9.1119",
language = "English (US)",
volume = "82",
pages = "1119--1123",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "9",

}

TY - JOUR

T1 - Allergen immunotherapy

AU - Rank, Matthew A

AU - Li, James T C

PY - 2007

Y1 - 2007

N2 - Allergen immunotherapy involves exposing a patient to a gradually escalating dose of a specific allergen with the intention of decreasing allergic and inflammatory responses, ultimately leading to a sustained decrease in allergic symptoms. A build-up phase (once weekly injections) is followed by a maintenance phase (once monthly injections) that generally continues for 3 to 5 years. Allergen immunotherapy is indicated for select patients with allergic rhinoconjunctivitis, allergic asthma, and stinging insect hypersensitivity. The safety and efficacy of allergen immunotherapy have been confirmed by numerous well-designed studies. Recent research has helped uncover the mechanisms by which allergen immunotherapy exerts its therapeutic effect, paving the way for the development of safer, more effective therapy for a wider range of allergic diseases.

AB - Allergen immunotherapy involves exposing a patient to a gradually escalating dose of a specific allergen with the intention of decreasing allergic and inflammatory responses, ultimately leading to a sustained decrease in allergic symptoms. A build-up phase (once weekly injections) is followed by a maintenance phase (once monthly injections) that generally continues for 3 to 5 years. Allergen immunotherapy is indicated for select patients with allergic rhinoconjunctivitis, allergic asthma, and stinging insect hypersensitivity. The safety and efficacy of allergen immunotherapy have been confirmed by numerous well-designed studies. Recent research has helped uncover the mechanisms by which allergen immunotherapy exerts its therapeutic effect, paving the way for the development of safer, more effective therapy for a wider range of allergic diseases.

UR - http://www.scopus.com/inward/record.url?scp=34548427766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548427766&partnerID=8YFLogxK

U2 - 10.4065/82.9.1119

DO - 10.4065/82.9.1119

M3 - Article

C2 - 17803880

AN - SCOPUS:34548427766

VL - 82

SP - 1119

EP - 1123

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 9

ER -